CLAIMS:

1. An anti-RSV antibody or antigen-binding fragment thereof, wherein:

RSV does not produce a virus that escapes neutralization by the antibody or antigen-binding fragment thereof after more than 10 or more rounds of viral replication in the presence of the antibody or antigen-binding fragment thereof, wherein:

the antibody or antigen-binding fragment comprises:

a variable heavy chain containing a VH CDR1 comprising the sequence of amino acid residues set forth in SEQ ID NO:405 or 437~~ or a sequence of amino acids having at least or at least 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:405 or 437~~; a VH CDR2 comprising the sequence of amino acid residues set forth in SEQ ID NO: 406~~ or a sequence of amino acids having at least or at least 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:406~~; and a VH CDR3 comprising the sequence of amino acid residues set forth in SEQ ID NO:407~~ or a sequence of amino acids having at least or at least 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:407~~; and

a variable light chain containing a VL CDR1 comprising the sequence of amino acids set forth in SEQ ID NO: 408~~ or a sequence of amino acids having at least or at least 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:408~~; a VL CDR2 comprising the sequence of amino acids set forth in SEQ ID NO:409~~ or a sequence of amino acids having at least or at least 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:409~~; and a VL CDR3 comprising the sequence of amino acids set forth in SEQ ID NO:410~~ or a sequence of amino acids having at least or at least 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:410~~; and

the antibody or antigen-binding fragment thereof immunospecifically binds to Respiratory Syncytial Virus (RSV) fusion (F) protein and/or neutralizes RSV.

2. The anti-RSV antibody or antigen-binding fragment of claim 1, comprising:

a VH domain, wherein the amino acid sequence of the VH domain is set forth in amino acids 1-121 of SEQ ID NO:396 ~~or is at least or 80%, 81%, 82%, 83%, 84%, 85%, 86%,~~

~~87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in amino acids 1-121 of SEQ ID NO:396~~; and

a VL domain, wherein the amino acid sequence of the VL domain is set forth in amino acids 1-110 of SEQ ID NO:395 ~~or is at least or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence set forth in amino acids 1-110 of SEQ ID NO:395~~.

7. Use of an antibody or antigen-binding fragment of claim 1 or 2 for formulation of a medicament for treating or inhibiting one or more symptoms of a RSV infection, or for preventing a RSV infection.

8. A method of detecting RSV infection comprising:

(a) assaying the level of RSV antigen in a fluid sample, cell sample, or tissue sample using an antibody or antigen-binding fragment of claim 1 or 2;

(b) comparing the assayed level of RSV antigen with a control level whereby an increase in the assayed level of RSV antigen compared to the control level of the RSV antigen is indicative of a RSV infection.

9. An isolated nucleic acid that encodes the antibody or antigen-binding fragment of claim 1 or 2.